- Home
- GUTS vs SLDB Comparison
GUTS vs SLDB Comparison
Compare GUTS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- SLDB
- Stock Information
- Founded
- GUTS 2010
- SLDB 2013
- Country
- GUTS United States
- SLDB United States
- Employees
- GUTS N/A
- SLDB N/A
- Industry
- GUTS
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUTS
- SLDB Health Care
- Exchange
- GUTS NYSE
- SLDB Nasdaq
- Market Cap
- GUTS 110.1M
- SLDB 124.7M
- IPO Year
- GUTS 2024
- SLDB 2018
- Fundamental
- Price
- GUTS $1.42
- SLDB $5.78
- Analyst Decision
- GUTS Buy
- SLDB Strong Buy
- Analyst Count
- GUTS 2
- SLDB 12
- Target Price
- GUTS $10.00
- SLDB $17.83
- AVG Volume (30 Days)
- GUTS 336.9K
- SLDB 5.4M
- Earning Date
- GUTS 03-04-2025
- SLDB 03-12-2025
- Dividend Yield
- GUTS N/A
- SLDB N/A
- EPS Growth
- GUTS N/A
- SLDB N/A
- EPS
- GUTS N/A
- SLDB N/A
- Revenue
- GUTS $97,000.00
- SLDB N/A
- Revenue This Year
- GUTS N/A
- SLDB N/A
- Revenue Next Year
- GUTS N/A
- SLDB N/A
- P/E Ratio
- GUTS N/A
- SLDB N/A
- Revenue Growth
- GUTS N/A
- SLDB N/A
- 52 Week Low
- GUTS $1.37
- SLDB $2.88
- 52 Week High
- GUTS $10.50
- SLDB $15.05
- Technical
- Relative Strength Index (RSI)
- GUTS 35.96
- SLDB 69.94
- Support Level
- GUTS $1.37
- SLDB $3.15
- Resistance Level
- GUTS $1.70
- SLDB $7.20
- Average True Range (ATR)
- GUTS 0.13
- SLDB 0.63
- MACD
- GUTS -0.01
- SLDB 0.37
- Stochastic Oscillator
- GUTS 11.11
- SLDB 67.13
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.